Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-07-11
2006-07-11
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S325000, C435S366000, C435S371000, C435S320100
Reexamination Certificate
active
07074618
ABSTRACT:
Adenovirus packaging cell lines for growth of E1A/E1B deficient adenovirus that is substantially free of replication competent adenovirus (RCA), are provided. Methods for producing adenovirus substantially free of RCA are also provided, wherein the adenovirus is grown in a cell line containing coding sequences for adenovirus E1A and E1B, are operably linked to promoters that lack polynucleotide sequences sharing substantial sequence identity with the native adenovirus E1A and E1B promoters.
REFERENCES:
patent: 5891690 (1999-04-01), Massie
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6265212 (2001-07-01), Fallaux et al.
patent: 2001/0049136 (2001-12-01), Imler et al.
patent: WO 95/34671 (1995-12-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/18418 (1996-06-01), None
Berkner et al., Development of Adenovirus Vectors for the Expression of Heterologous Genes, Biotechniques, 1988, 6: 616-629.
Fallaux et al., “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Component Adenoviruses,” Human Gene Therapy, 1998, 9:1909-1917.
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. General Virology, 1977, 36:59-72.
Kim et al, “Development of a packaging cell line for propagation of replication-deficient adenovirus vector”, Exp. Mol. Med., 2001, 33(3)145-9.
Kozarsky et al., “Gene therapy: adenovirus vectors,” Curr. Opin. Genet. Dev., 1993, 3: 499-503.
Schiedner et al., “Efficient Transformation of Primary Human Amniocytes by E1 Functions of Ad5: Generation of New Cell Lines for Adenoviral Vector Production,” Human Gene Therapy, 2000, 11:2105-2116.
Yu et al., “Selectively replicating oncolytic adenoviruses as cancer therapeutics,” Curr. Opin. Mol. Ther., 2002, 4(5):435-443.
Gorziglia, et al., “Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy”, Journal of Virology, vol. 70, No. 6, pp. 4173-4178, 1996.
Murakami, et al., “A Single Short Stretch of Homology Between Adenoviral Vector and Packaging Cell Line Can Give Rise to Cytopathic Effect-Inducing, Helper-Dependent E1-Positive Particles”, Human Gene Therapy, vol. 13, pp. 909-920, 2002.
Louis, et al., “Cloning and Sequencing of the Cellular-Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line”, Virology, vol. 233, pp. 423-429, 1997.
Hehir, et al., “Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modifications To Prevent Their Occurrence”, Journal of Virology, vol. 70, No. 12, pp. 8459-8467, 1996.
Farson Deborah
Li Yuanhao
Tao Luqun
Yu De-Chao
Cell Genesys Inc.
Guzo David
LandOfFree
Adenoviral E1A/E1B complementing cell line does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenoviral E1A/E1B complementing cell line, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenoviral E1A/E1B complementing cell line will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3534585